KRAS and BRAF Mutation Screening In Metastatic Colorectal Cancer Costly In Relation To Benefits

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute...



Cancer-Medicine in USA